Abstract:CRISPR/Cas9 is a recently discovered genomic editing technique that altered scientist's sight in studying genes function. Cas9 is controlled via guide (g) RNAs, which match the DNA targeted in cleavage to modify the respective gene. The development in prostate cancer (PC) modeling directed not only to novel resources for recognizing the signaling pathways overriding prostate cell carcinoma, but it has also created a vast reservoir for complementary tools to examine therapies counteracting this type of cancer. Various cultured somatic rat models for prostate cancer have been developed that nearly mimic human prostate cancer. Nano-medicine can passively target cancer cells via increasing bioavailability and conjugation via specific legend, contributing to reduced systemic side-effects and increased efficacy. This article highlights liposomal loaded Nano-medicine as a potential treatment for prostate cancer and clarifies the CRISPR/Cas9 variation accompanied with prostate cancer. PC is induced experimentally in western rat model via ethinyl estradiol for 4 weeks and SC. dose of 3, 2'- dimethyl-4-aminobiphenyl estradiol (DAE) (50mg/kg) followed by treatment via targeted liposomal-coated compounds such as liposomal dexamethasone (DXM), liposomal doxorubicin (DOX) and liposomal Turmeric (TUR) (3mg/kg IP) for four weeks in a comparative study to their non-targeted analogue dexamethasone, doxorubicin and Turmeric. 3, 2'- dimethyl-4-aminobiphenylestradiol elicit prostate cancer in western rats within 5 months. Simultaneous supplementations with these liposomal compounds influence on prostate cancer; tumor markers were investigated via prostate-specific antigen (PSA), Nitric oxide (NOX) and CRISPR/Cas9 gene editing. Several long non-coding RNAs were reported to be deregulated in prostate cell carcinoma, including MALAT1. On the other hand, gene expression of apoptotic biomarkers focal adhesion kinase (AKT-1), phosphatidylinistol kinase (PI3K) and glycogen synthase kinase-3 (GSK-3) was also investigated and further confirming these results via histopathological examination. Liposomal loaded dexamethasone; doxorubicin and Turmeric can be considered as promising therapeutic agents for prostate cancer via modulating CRISPR/Cas9 gene editing and long non coding gene MALAT1.

In Vitro Prostate Cancer Treatment via CRISPR-Cas9 Gene Editing Facilitated by Polyethyleneimine-Derived Graphene Quantum Dots

(Invited) CRISPR-Cas9-Based Cancer Therapy Delivery By Carbon Nanomaterials

Chain-shattering Pt(IV)-backboned polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic cancer therapy

Quaternary ammonium-based nanosystem enables delivery of CRISPR/Cas9 for cancer therapy

Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid Via a Gold Nanocluster/Lipid Core-Shell Nanocarrier

Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Lipid Nanoparticle-Mediated Efficient Delivery of CRISPR/Cas9 for Tumor Therapy

A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy

Targeted Delivery of CRISPR/Cas9 to Prostate Cancer by Modified Grna Using a Flexible Aptamer-Cationic Liposome

CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy

Effective Genome Editing Using CRISPR-Cas9 Nanoflowers

Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy

Genome Editing of Mutant KRAS Through Supramolecular Polymer-Mediated Delivery of Cas9 Ribonucleoprotein for Colorectal Cancer Therapy.

Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion

A Dual-Targeting Delivery System for Effective Genome Editing and in Situ Detecting Related Protein Expression in Edited Cells.

CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer

Ultra-efficient Delivery of CRISPR/Cas9 Using Ionic Liquid Conjugated Polymers for Genome Editing-Based Tumor Therapy

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment